Founding Partner
Oxbryta (voxelotor) is a prescription medication approved to treat sickle cell disease (SCD), a severe genetic disorder that affects red blood cell shape and function. While Oxbryta was designed to improve blood flow and reduce anemia-related complications, alarming reports link the drug to serious side effects, including organ failure, stroke, arthritis, and even wrongful death. Patients and their families deserve to understand these risks and their legal options if harm occurs.
Our attorneys are here to help you hold manufacturers accountable. Product liability laws exist to ensure that companies are responsible for the safety of their products.
When these standards are not met, and individuals suffer as a result, victims may pursue legal action for justice and compensation. Parker Waichman LLP’s defective drug attorneys are committed to guiding clients through this process, helping them obtain the relief they need to address the harm they’ve suffered. Call 800-968-7529 today to begin your path toward accountability and recovery.
Oxbryta was approved by the FDA in 2019 as the first drug in its class to specifically address the root causes of SCD-related complications. Its innovative approach targets hemoglobin polymerization, a key factor in the formation of sickled cells. By preventing this polymerization, Oxbryta reduces the likelihood of red blood cells assuming their abnormal, crescent shape, thereby improving blood flow and oxygen transport.
The drug binds directly to hemoglobin molecules, increasing their ability to carry oxygen. This not only alleviates anemia but also reduces the stress on vital organs caused by inadequate oxygenation.
Patients who respond well to Oxbryta may experience:
However, despite these intended benefits, reports of severe complications highlight the need for increased scrutiny of its safety.
For patients, the news of Oxbryta’s potential risks is devastating. Sickle cell disease itself is a chronic, painful condition, and individuals dealing with it often struggle with debilitating health impacts that affect their daily lives. Many turned to Oxbryta, hopeful it would alleviate some of the disease’s challenges, only to encounter heightened risk factors that worsened their situation.
One of the most troubling aspects is the increased rate of VOCs observed in Oxbryta users. These crises, marked by excruciating pain and limited oxygen delivery to tissues, can lead to organ damage, infections, and even death. The post-marketing studies not only highlighted a rise in VOCs but also noted a higher mortality rate in patients using Oxbryta compared to those on a placebo. For those impacted, the consequences go beyond physical pain, as the emotional and psychological toll of worsening health and diminishing treatment options are profound. Many patients and their families feel betrayed, having trusted a medication that has instead exposed them to grave risks.
Vaso-occlusive crises (VOCs) are one of the most severe complications associated with sickle cell disease, and they can lead to life-threatening outcomes. For patients who took Oxbryta and experienced VOCs or other severe side effects, understanding the symptoms and risks is essential for recognizing the full impact of these crises. VOCs occur when misshapen or “sickled” red blood cells block blood vessels, reducing oxygen flow to tissues and causing intense pain. Unfortunately, data from post-marketing studies have shown that patients taking Oxbryta experienced higher rates of these painful episodes compared to those on a placebo.
Patients experiencing a vaso-occlusive crisis may face a range of symptoms, often starting with severe, localized pain in areas with limited blood flow. Common symptoms include:
One of the most alarming risks associated with Oxbryta is organ failure, particularly affecting the liver and kidneys. The drug’s impact on blood flow and oxygen delivery can inadvertently deprive vital organs of the resources they need to function properly.
Patients experiencing these symptoms should seek immediate medical attention, as organ failure can escalate rapidly without intervention.
Complications from Oxbryta, such as organ failure, stroke, or severe vaso-occlusive events, can have fatal consequences. Families who have lost loved ones due to these complications often struggle with unanswered questions about the drug’s safety and whether proper warnings were provided.
Oxbryta has been linked to an increased risk of strokes, particularly ischemic strokes caused by blood clots obstructing brain blood flow.
Patients have reported joint pain, swelling, and stiffness while taking Oxbryta, potentially indicating immune or inflammatory reactions. These symptoms can severely limit mobility and quality of life, often requiring additional medical intervention.
Even after discontinuing Oxbryta, patients may face lasting health challenges, including chronic pain, organ dysfunction, and an elevated risk of stroke or other vascular complications. For those harmed by Oxbryta, the higher frequency of VOCs and associated risks may signal that they’ve been affected by the medication’s unexpected side effects. Recognizing these symptoms and seeking medical documentation is crucial for those who may be considering a legal claim related to Oxbryta’s adverse effects.
Patients harmed by Oxbryta may have a legal pathway to seek compensation through a product liability lawsuit. These cases allow victims to pursue damages for the physical, emotional, and financial hardships suffered due to a product’s failure to meet safety standards. Filing a lawsuit against a major corporation like Pfizer can feel overwhelming, but an attorney skilled in product liability law can guide victims through every step of the process, advocating on their behalf and ensuring they receive fair compensation.
At Parker Waichman LLP, we are committed to providing comprehensive legal support throughout the entire lawsuit process, which, though complex, offers victims a means to seek justice. Our approach begins with a thorough case evaluation, where we review medical records, evidence of product usage, and expert opinions to understand how Oxbryta caused your injury and identify the responsible parties. This initial investigation is crucial for building a strong foundation for your case.
Once we have gathered sufficient evidence, our attorneys develop a compelling case that illustrates how the medication’s risks were misrepresented or insufficiently disclosed and highlights the product’s failure to meet safety standards. Demonstrating the manufacturer’s failure in its duty of care is essential to showing why you are entitled to compensation for your injuries.
Negotiation plays a significant role in the lawsuit process, as many product liability cases are settled outside of court. Our Oxbryta attorneys are skilled negotiators who will work to reach a fair settlement with the manufacturer, ensuring that any offer addresses the full scope of harm you’ve experienced. However, if a fair settlement cannot be reached, we are prepared to represent you in court. Our experienced Oxbryta lawsuit lawyers are adept at presenting complex product liability cases, fighting to secure the compensation you deserve.
Having legal representation is vital in these cases due to the intricate legal and medical issues involved. An Oxbryta attorney not only strengthens your case but also alleviates much of the burden, allowing you to focus on recovery while they manage the legal complexities. At Parker Waichman LLP, our goal is to provide you with the dedicated support needed to navigate the legal process and achieve the best possible outcome for your case.
Navigating a product liability lawsuit requires a deep understanding of both medical and legal factors. A skilled attorney can provide essential guidance, building a case that demonstrates not only the harmful impact of Oxbryta but also the manufacturer’s liability for those harms. Legal representation is particularly important when facing a corporation with substantial legal resources, as an attorney will balance the scales and advocate for fair treatment of the victim’s claims.
Pursuing compensation for product liability damages can offer patients and their families financial relief, support for continued medical care, and a sense of justice after the pain and betrayal they experienced. While no compensation can reverse the harm done, it can help secure a better quality of life moving forward.
When it comes to representing clients in injury cases, Parker Waichman LLP offers an unwavering commitment to achieving the best possible outcome. With a national reach and a strong presence in New York, our firm has assisted countless individuals and families in navigating the legal system, fighting for justice, and securing substantial compensation. Our team is ready to support you with a free, no-obligation consultation to discuss your unique case and outline your legal options.
At Parker Waichman LLP, you can trust that every detail of your case is managed with precision and care. Our dedicated attorneys build the strongest possible case on your behalf, and our results speak volumes: We’ve recovered over $2 billion in settlements and verdicts for clients. When you work with us, you’re choosing one of the nation’s top personal injury firms, known for our tenacity, skill, and commitment to achieving justice for our clients.
Our firm operates on a contingency-fee basis, meaning we only get paid if we win your case. There are no upfront costs, and you’ll never be responsible for legal fees out of pocket. If we succeed in securing compensation for you, our fee comes from a portion of your settlement or award, not from your bank account. If we don’t win, you owe us nothing, making our services accessible to anyone in need of top-notch representation.
With decades of experience in personal injury law, our attorneys have successfully represented clients in both state and federal courts. We’ve handled cases with complexities and challenges similar to yours, so we understand what’s needed to build a winning strategy. Our team’s judgment, skills, and experience are unparalleled, making us a trusted choice for anyone seeking effective and knowledgeable representation.
The legal community recognizes Parker Waichman LLP for our excellence, and our reputation is backed by countless accolades. Our attorneys have been honored by industry peers, judges, insurance companies, and clients alike. We’ve received some of the highest ratings in the field, including near-perfect ratings from AVVO, Martindale-Hubbell’s highest peer-review rating, and Law Dragon’s prestigious “5 Dragons” rating. As one of the top personal injury firms in the country, we’re proud to be recognized by Best Lawyers and other leading authorities in the legal industry.
Parker Waichman LLP
If you or a loved one has been injured in an accident or have been injured by another party in some other way, we are here to stand up for your rights. Our personal injury attorneys have been representing injury victims and their families in Long Island and throughout the nation since the early 1980s.
While the FDA approved Oxbryta for treating SCD in patients 12 years and older, the agency continues to monitor its post-market safety profile. The drug’s approval was based on promising clinical trial data showing its ability to improve hemoglobin levels and reduce anemia. However, early trials noted potential side effects, including headache, diarrhea, and fatigue, and did not fully account for long-term risks.
As post-market reports accumulate, concerns about severe adverse effects such as organ damage, stroke, and arthritis have prompted calls for further investigation. The FDA has not yet issued a black box warning or recall for Oxbryta, but the agency encourages healthcare providers to report adverse events through the MedWatch program to better understand the drug’s safety risks.
Recent patient and healthcare provider reports have identified several unanticipated risks associated with Oxbryta, including:
The growing body of evidence underscores the importance of ongoing research and transparency regarding Oxbryta’s risks.
On September 26, 2024, the FDA issued an alert to patients, caregivers, and healthcare providers regarding the voluntary market withdrawal of Oxbryta (voxelotor) due to emerging safety concerns. Healthcare professionals are advised to discontinue prescribing Oxbryta, and patients should consult their healthcare providers to discuss stopping Oxbryta and transitioning to an alternative treatment.
Pfizer Inc., the manufacturer of Oxbryta, has announced the cessation of all distribution, active clinical trials, and expanded access programs for the drug. This decision follows new data indicating that the risks associated with Oxbryta outweigh its benefits for patients with sickle cell disease.
Postmarketing clinical trials revealed a higher occurrence of vaso-occlusive crises (severe episodes of pain caused by sickled red blood cells obstructing blood flow and oxygen delivery) in patients treated with Oxbryta compared to those receiving a placebo. Additionally, a greater number of deaths were reported in the Oxbryta treatment group. Similar findings of increased vaso-occlusive crises were observed in two real-world registry studies. Based on this collective clinical evidence, Pfizer determined that Oxbryta’s risks outweigh its potential benefits.
The FDA is currently conducting an in-depth safety review of the postmarketing clinical trial data, real-world registry findings, and adverse event reports from the FDA Adverse Event Reporting System (FAERS). Any additional conclusions or necessary communications will follow the completion of this review.
Oxbryta initially received FDA accelerated approval in 2019 for treating sickle cell disease in adults and pediatric patients aged 12 and older. In 2021, the FDA expanded this approval to include children aged 4 to 11. The accelerated approval program is designed to facilitate earlier access to drugs addressing serious conditions by relying on surrogate or intermediate clinical endpoints that are likely to predict clinical benefit. However, these approvals require postmarketing studies to confirm the clinical value of the medications.
The FDA recognizes the critical need for safe and effective treatments for sickle cell disease and emphasizes the availability of other approved medications that healthcare providers can consider as alternative therapies for their patients.
If you or someone you love has been harmed by Oxbryta, the Oxbryta injury and wrongful death lawsuit lawyers at Parker Waichman LLP are here to help.
As a nationally recognized law firm, we are dedicated to securing justice for victims of dangerous pharmaceuticals. Contact us today for a free, no-obligation consultation to discuss your case, legal rights, and options for pursuing compensation.
Call 800-968-7529 to speak with our team and take the first step toward holding the manufacturer accountable.
Parker Waichman LLP
Our law firm is ready to represent you in your injury case. We’ve helped many New York residents as well as those needing help nationwide. Contact our team for a free case consultation today.
I had a great experience with them , everyone was very helpful and sweet.
Michelle Murphy
4 months ago
Zarahi was very professional and very Quick and very knowledgeable i realy appreciated her patience and perseverance she Deserves 100 stars 🌟 but since i can only send 5 i Guess i will just have to send that truly yours Rashine Downs
Kush Three
6 months ago
VERY NICE WORK PLACE THEY HAVE BEEN GOOD TO MY MOM
Whitney Brinson
5 years ago
They treated me with tender love and care
Terrell Weaver
2 months ago
Wonderful people. They made the whole process if dealing with a gov’t agency so easy. Special compliments to Gina Viti
Michael Ross
2 months ago
I’m a 9/11 first responder, and I can honestly say that Parker Waichman made me feel like they had my best interest in my VCF case. Ms Candalino & Ms Viti are top notch in my book. I was constantly informed on the status of my case. I would definitely recommend Parker Waichman LLP to family and friends.
D D
6 years ago
We have the experience and the skilled litigators to win your case. Contact us and speak with a real attorney who can help you.
Parker Waichman LLP
6 Harbor Park Drive
Port Washington, NY 11050
Parker Waichman LLP
201 Old Country Road – Suite 145
Melville, NY 11747
Parker Waichman LLP
300 Cadman Plaza West
One Pierrepont Plaza, 12th Floor
Brooklyn, NY 11201
Parker Waichman LLP
27299 Riverview Center Boulevard, Suite 108
Bonita Springs, FL 34134
We handle mass torts cases nationwide. Please contact our office to learn more.